This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


CSL Limited

Description: Sandovac is a seasonal vaccine for the prevention of influenza infections.

Deal Structure: CSL and Novartis
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.In August 2015, CSL announced that it has closed ts transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

Sequirus and Valneva
In August 2016, Valneva announced the signing of an agreement with Seqirus for the marketing & distribution of Seqirus seasonal flu vaccines Sandovac and Fluad in the Austrian market.

Partners: Valneva SE

Sandovac News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug